title: Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
abstract: Hepatitis B virus (HBV) reactivation occurs commonly in patients with non-Hodgkin lymphoma, receiving rituximab-based therapeutic regimen. Guidelines from different organizations are not all in agreement with regard to screening and antiviral prophylaxis, given the limited evidence. Antiviral prophylaxis has been recommended for all HBV surface antigen-positive patients. Evidence for benefit from prophylaxis has recently been recognized among HBV surface antigen-negative/HBV core antibody-positive patients. Incidence of HBV reactivation varies in different geographical locations and the decision to start antiviral prophylaxis should consider local incidence data. Given the increased rates of rituximab-associated HBV reactivation and potentially fatal outcome, it is prudent that all patients who receive rituximab should be screened for HBV markers.
authors.affiliation: Department of Internal Medicine, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit Medical Center, Detroit, MI 48201, USA.
authors.forename: Joseph Adrian Lumawig
authors.initials: JA
authors.lastname: Buensalido
authors.forename: Pranatharthi H
authors.initials: PH
authors.lastname: Chandrasekar
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000037:antagonists & inhibitors; D004334:Drug Administration Schedule; D006509:Hepatitis B / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006512:Hepatitis B Core Antigens / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017410:Practice Guidelines as Topic; D000069283:Rituximab; D014611:Vaccination; D014775:Virus Activation / Q000187:drug effects
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000998:Antiviral Agents; D004279:DNA, Viral; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D007155:Immunologic Factors; D000069283:Rituximab